AVI BioPharma's President to Present Company Milestones at U.S. Bancorp Piper Jaffray Health Care Conference
Portland, Ore., January 30, 2002 - AVI BioPharma, Inc. (NASDAQ: AVII, AVIIW, AVIIZ) has announced that Alan P. Timmins, AVI's President and Chief Operating Officer will present at the fifth annual U.S. Bancorp Piper Jaffray Health Care Conference today in New York City. Timmins will provide an overview of AVI and discuss the company's clinical development profile, its current antisense work and ongoing drug development plans.
"AVI has reached a number of critical business and scientific milestones over the past year", said Timmins. "U.S. Bancorp Piper Jaffray's prestigious conference provides an important forum to discuss our goals for the company in 2002."
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: cancer immunotherapy and gene-targeted drugs. Its lead clinical agent, AVICINE™, a therapeutic cancer vaccine, has completed two Phase II trials in pancreatic cancer and is in a Phase III trial in colorectal cancer. The first application of its NeuGene compounds, Resten-NG, is designed to treat cancer, cardiovascular restenosis and other cell proliferation disorders. More information about AVI is available on the Company's Web site at www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of pre-clinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Security and Exchange Commission filings.